Santhera Collaborates with Sperogenix to Develop and Commercialize Vamorolone for Rare Diseases in the Greater China
Shots:
- Santhera to receive ~$124M, including upfront and DMD related US related milestones amounting to $20M along with royalties on sales in the licensed territories
- Sperogenix to get exclusive development & commercialization rights to vamorolone in DMD and all other rare disease indications for Greater China. Santhera will lead manufacturing and supply while Sperogenix will focus on R&D work and future commercialization
- Santhera continues to bring vamorolone to patients in the US and EU, with a rolling NDA submission to be started in Q1’22, while collaborating for additional markets globally
Ref: Globe Newswire | Image: Businesswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
